Alternatively, downregulation of EGFRvIII activation at both tyrosine phosphorylation and expression levels by the combination treatment may be important to suppress the signaling from EGFR that contributes to growth and survival benefits for glioma cells in vivo. This evidence concerns the gene EGFR and glioma.